Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin iota chain (VPREB1) is a 126-amino acid protein (16-18 kDa), encoded by the VPREB1 gene on chromosome 22. It is expressed selectively during the early stages of B cell development (pro-B and early pre-B cells), where it forms a non-covalent complex with CD179b (lambda5), known as the surrogate (or pseudo) light chain. Together, VPREB1 and CD179b associate with the Ig mu heavy chain and signal transducers (CD79a/CD79b) to produce the pre-B cell receptor (preBCR), essential for B lymphocyte maturation. This receptor complex regulates immunoglobulin gene rearrangement, allelic exclusion at the Ig heavy chain locus, and promotes Ig light chain gene rearrangements, acting as a functional checkpoint in B cell development. No human diseases are directly linked exclusively to VPREB1 mutations or dysfunction, but deficiencies in associated components result in severe impairment of B cell development, leading to immunodeficiencies such as agammaglobulinemia. VPREB1 is considered a diagnostic marker in some forms of leukemia and immune disorders, though it is not currently a direct therapeutic drug target[1][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin iota chain (VPREB1).